Abstract
In this issue of Blood, Röth et al show in a phase 1/2 trial that crovalimab, a subcutaneously administered monoclonal antibody that targets C5, is safe and effective in treating paroxysmal nocturnal hemoglobinuria (PNH).1 Crovalimab targets a C5 epitope that is different from the IV C5 inhibitors, eculizumab and ravulizumab. Crovalimab is administered subcutaneously every 4 weeks.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 884-885 |
| Number of pages | 2 |
| Journal | Blood |
| Volume | 135 |
| Issue number | 12 |
| DOIs | |
| State | Published - Mar 19 2020 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology